RS BioTherapeutics

RS BioTherapeutics is a Maryland-based company leveraging its understanding of the endocannabinoid system (ECS) to develop pharmaceuticals. The first investigational compound from RS BioTherapeutics (RSBT-001) is an inhaled, semi-synthetic cannabinolic acid complex intended for treating acute and chronic pulmonary inflammation associated with respiratory conditions, including COPD, SARS-CoV-2, cystic fibrosis, asthma, bronchitis, and acute respiratory distress syndrome.